Skip to Main Content

A federal court judge dismissed all claims against dozens of generic manufacturers and retailers in sprawling litigation over allegations that the Zantac heartburn pill may contain a carcinogen, although brand-name drug makers will continue to face more than 1,400 lawsuits over the issue.

The ruling is the latest chapter in an ongoing saga over the safety of the widely used heartburn medicine, which is also known as ranitidine. The pills were recalled by numerous manufacturers in 2019 after the Food and Drug Administration found some contained higher than acceptable levels of NDMA,  an organic chemical that is part of a carcinogenic group of compounds called N-nitrosamines. The agency acted after an online pharmacy discovered the impurity by testing batches and urged the FDA to act.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment